Shares of Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating.

Brokers have set a 1 year consensus target price of $32.33 for the company, according to Zacks. Zacks has also given Dova Pharmaceuticals an industry rank of 100 out of 265 based on the ratings given to related companies.

A number of research firms have weighed in on DOVA. J P Morgan Chase & Co began coverage on shares of Dova Pharmaceuticals in a research note on Monday, July 24th. They set an “overweight” rating and a $35.00 price target on the stock. Leerink Swann raised shares of Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 price target on the stock in a research note on Tuesday, September 26th. Finally, Jefferies Group LLC began coverage on shares of Dova Pharmaceuticals in a research note on Monday, July 24th. They set a “buy” rating and a $30.00 price target on the stock.

Dova Pharmaceuticals (NASDAQ:DOVA) traded up 0.69% during mid-day trading on Thursday, reaching $26.22. 36,427 shares of the company traded hands. Dova Pharmaceuticals has a 52-week low of $18.18 and a 52-week high of $28.24. The stock’s market capitalization is $672.60 million. The stock has a 50-day moving average of $25.33 and a 200 day moving average of $24.45.

Dova Pharmaceuticals (NASDAQ:DOVA) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.08). Equities research analysts expect that Dova Pharmaceuticals will post ($1.40) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Zacks: Dova Pharmaceuticals, Inc. (DOVA) Given $32.33 Average Price Target by Brokerages” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/05/zacks-dova-pharmaceuticals-inc-dova-given-32-33-average-price-target-by-brokerages.html.

In related news, Director Steven M. Goldman purchased 20,169 shares of the business’s stock in a transaction on Tuesday, August 15th. The shares were bought at an average price of $22.23 per share, with a total value of $448,356.87. Following the completion of the purchase, the director now directly owns 81,158 shares in the company, valued at approximately $1,804,142.34. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Paul B. Manning purchased 25,870 shares of the business’s stock in a transaction on Wednesday, August 16th. The shares were bought at an average cost of $22.30 per share, for a total transaction of $576,901.00. The disclosure for this purchase can be found here.

A number of large investors have recently bought and sold shares of the business. Conning Inc. acquired a new stake in shares of Dova Pharmaceuticals in the second quarter worth $1,115,000. JPMorgan Chase & Co. acquired a new stake in shares of Dova Pharmaceuticals in the second quarter worth $382,000. Sphera Funds Management LTD. acquired a new stake in shares of Dova Pharmaceuticals in the second quarter worth $2,118,000. Pier Capital LLC acquired a new stake in shares of Dova Pharmaceuticals in the second quarter worth $1,191,000. Finally, Wells Fargo & Company MN acquired a new stake in shares of Dova Pharmaceuticals in the second quarter worth $4,458,000. 23.52% of the stock is currently owned by institutional investors.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Get a free copy of the Zacks research report on Dova Pharmaceuticals (DOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.